LONDON, Aug. 21 /PRNewswire-FirstCall/ -- SkyePharma PLC announces that Ernst & Young LLP has been selected as the Company’s auditor. The new auditor will be responsible for reviewing the Company’s unaudited interim results for the six months ended 30 June 2006, to be announced in late September.
For further information please contact: SkyePharma PLC +44 207 491 1777 Peter Laing, Director of Corporate Communications 44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now twelve approved products incorporating SkyePharma’s technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com.
SkyePharma PLC
CONTACT: Peter Laing, Director of Corporate Communications,+44-207-491-5124, or Sandra Haughton, US Investor Relations,+1-212-753-5780, both of SkyePharma PLC, +44-207-491-1777; or Tim Anderson,Mark Court, Rebecca Skye Dietrich, all of Buchanan Communications forSkyePharma PLC, +44-207-466-5000
Web site: http://www.skyepharma.com/
